Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 6/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8053624 | 0.90 | ELANE (0.49) | KDM4EALDH1A1SMN1; SMN2ELANEGAA | |
| SCHEMBL8228763 | 0.83 | ELANE (0.47) | KDM4EALDH1A1SMN1; SMN2ELANEGAA | |
| SCHEMBL2272178 | 0.83 | ELANE (0.56) | KDM4EALDH1A1SMN1; SMN2ELANENOTUM | |
| SCHEMBL4152986 | 0.82 | ELANE (0.50) | ELANENOTUM | |
| SCHEMBL8065761 | 0.81 | KDM4E (0.42) | KDM4EALDH1A1SMN1; SMN2ELANEGAA | |
| SCHEMBL4137643 | 0.81 | PDE4B (0.50) | SMN1; SMN2ELANENOTUM | |
| SCHEMBL984085 | 0.79 | NOTUM (0.64) | ELANENOTUM | |
| SCHEMBL8234302 | 0.79 | ALDH1A1 (0.48) | KDM4EALDH1A1SMN1; SMN2ELANEGAA | |
| SCHEMBL8228754 | 0.79 | KDM4E (0.48) | KDM4EALDH1A1SMN1; SMN2ELANEGAA | |
| SCHEMBL8229059 | 0.79 | NOTUM (0.51) | KDM4EELANEGAANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436024-B2 | 2-pyridone compounds | ASTRAZENECA AB (GB) | 2013-05-07 | — | — | US | disclosed |
| US-8436024-B2 | 2-pyridone compounds | ASTRAZENECA AB (GB) | 2013-05-07 | — | — | US | disclosed |
| US-8436024-B2 | 2-pyridone compounds | ASTRAZENECA AB (GB) | 2013-05-07 | — | — | US | disclosed |
| EP-2483244-A1 | 2-PYRIDONE COMPOUNDS USED AS INHIBITORS OF NEUTROPHIL ELASTASE | AstraZeneca AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011039528-A1 | 2-PYRIDONE COMPOUNDS USED AS INHIBITORS OF NEUTROPHIL ELASTASE | ASTRAZENECA AB (SE) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011039528-A1 | 2-PYRIDONE COMPOUNDS USED AS INHIBITORS OF NEUTROPHIL ELASTASE | ASTRAZENECA AB (SE) | 2011-04-07 | — | — | WO | disclosed |
| US-20110082155-A1 | Novel 2-Pyridone Compounds | ASTRAZENECA AB (SE) | 2011-04-07 | — | — | US | disclosed |
| US-20110082155-A1 | Novel 2-Pyridone Compounds | ASTRAZENECA AB (SE) | 2011-04-07 | — | — | US | disclosed |
| US-20110082155-A1 | Novel 2-Pyridone Compounds | ASTRAZENECA AB (SE) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082155-A1 | Novel 2-Pyridone Compounds | SERPINB1, ELANE, EPX | KDM4E 1513/4885ALDH1A1 1872/4885SMN1; SMN2 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.